The authors concluded that that standard chemotherapy with CMF or AC resulted in superior RFS compared with capecitabine in older women with early-stage breast cancer and that the major benefit of standard chemotherapy was seen among patients with hormone receptor-negative disease. The gene discussed is NR4A1; the disease is breast carcinoma.